Graticule Asia Macro Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Graticule Asia Macro Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-95,000	Closed	-$8.44M	–	103
2019 Q1	$8.44M	Buy	+95,000	New	+$8.8M	0.6%	41
2016 Q4	–	Sell	-16,000	Closed	-$1.48M	–	114
2016 Q3	$1.48M	Buy	+16,000	New	+$1.51M	0.1%	72
2016 Q2	–	Sell	-220,000	Closed	-$18.1M	–	59
2016 Q1	$18.1M	Buy	+220,000	New	+$17.9M	1.42%	20
2015 Q3	–	Sell	-80,000	Closed	-$10.9M	–	101
2015 Q2	$10.9M	Buy	+80,000	New	+$9.91M	0.53%	33

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Graticule Asia Macro Advisors's BMRN Position: Q2 2019 in Review

Graticule Asia Macro Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 11,000 shares — an estimated $977K sold.

Graticule Asia Macro Advisors first reported a position in BMRN in Q2 2015 and held it in 5 quarters. The position peaked at $6.57M in Q2 2015. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

Graticule Asia Macro Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Graticule Asia Macro Advisors sold 11,000 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $977K.
Graticule Asia Macro Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Graticule Asia Macro Advisors's BioMarin Pharmaceuticals position peaked at $6.57M in Q2 2015.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.